Drug Discovery Targeting Drug-Resistant Bacteria explores the status and possible future of developments in fighting drug-resistant bacteria. The book covers the majority of microbial diseases and the drugs targeting them. In addition, it discusses the potential targeting strategies and innovative approaches to address drug resistance. It brings together academic and industrial experts working on discovering and developing drugs targeting drug-resistant (DR) bacterial pathogens. New drugs active against drug-resistant pathogens are discussed, along with new strategies being used to discover molecules acting via new modes of action. In addition, alternative therapies such as peptides and phages are included.
Pharmaceutical scientists, microbiologists, medical professionals, pathologists, researchers in the field of drug discovery, infectious diseases and microbial drug discovery both in academia and in industrial settings will find this book helpful.
Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.
1. What are drugs and why are they required? 2. Drugs against gram-negative bacteria 3. Drugs targeting gram-positive bacteria 4. Drug repurposing against bacteria 5. Drugs against M. tuberculosis 6. Drugs against TB and Bioweapons 7. New approaches to drug discovery: Peptides/quorum sensing/virulence 8. New strategies and targets for antibacterial discovery 9. Targeting efflux pumps for AMR 10. Discovering antibiotics from Phages 11. Drugs against non-tuberculous mycobacteria
Dr. Prashant Kesharwani is Assistant Professor of Pharmaceutics at the School of Pharmaceutical Education and Research, Jamia Hamdard University, New Delhi, India. He has published more than 150 articles in well reputed international journals and edited 10 international books. Dr. Kesharwani has received several awards, including the 'Ramanujan Fellowship, DST, India-2017', 'Excellence Research Award 2014', 'Young Innovator Award (Gold medal) 2012', 'International Travel Award/Grant from DST (New Delhi) and INSA (CCSTDS, Chennai) 2012', as well as receiving an ICMR Senior Research Fellowship (PhD) and AICTE Junior Research Fellowship (M. Pharm.). He has presented invited talks and presentations at prestigious conferences, supervised students/junior researchers, and actively participated in outreach and scientific dissemination for the service of the wider community. Dr. Kesharwani's current research is focused on the development of nano-engineered drug delivery systems for various diseases.
Sidharth Chopra Senior Scientist, Division of Microbiology, CSIR-Central Drug Research Institute, Lucknow, India.
Dr. Sidharth Chopra is a Senior Scientist, at Division of Microbiology, CSIR-Central Drug Research Institute, Lucknow, India. He has ~35 international publications in well reputed journals. One of his article is published in Bioresource technology 77 (3), 215-227 with 999 citations and he has extensively worked on discovery and development of NCE against ESKAPE, mycobacterial infections as well as biothreat pathogens.
Arunava Dasgupta Senior Scientist, Division of Microbiology, CSIR-Central Drug Research Institute, Lucknow, India.
Dr. Arunava Dasgupta a Senior Scientist, at Division of Microbiology, CSIR-Central Drug Research Institute, Lucknow, India. He has ~20 international publications in well reputed journals. He has extensively worked on discovery and development of NCE against mycobacterial infections as well as understanding hostpathogen interaction.